LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Isabelle Laure Ray-Coquard, Alexandra Léary, Sandro Pignata, Claire Cropet, Andrew Martin, Gerhard Bogner, Hiroyuki Yoshida, Ignace Vergote, N. Colombo, Jenni Mäenpää, Frédèric Selle, Barbara Schmalfeldt, Giovanni Scambia, Eva María Guerra Alia, Claudia Lefeuvre‐Plesse, A. Belau, Alain Lortholary, Martina Gropp‐Meier, Éric Pujade-Lauraine, P. Harter